Next Issue
Volume 12, 11
Previous Issue
Volume 12, 09
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
0.4
Journals
Cardiovascular Medicine
Volume 12
Issue 10
cardiovascmed-logo

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement
Cardiovascular Medicine is published by MDPI from Volume 28 Issue 1 (2025). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Editores Medicorum Helveticorum (EMH).

Cardiovasc. Med., Volume 12, Issue 10 (10 2009) – 7 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
2 pages, 186 KB  
Communication
Annual Report 2008 of the Swiss Society of Cardiology’s Working Group on “Cardiovascular Nursing and Allied Professions”
by Marcia E. Leventhal, Nicolas Masson, Wibke Reigber, Christine Mathis and Brigitte Eggimann
Cardiovasc. Med. 2009, 12(10), 284; https://doi.org/10.4414/cvm.2009.01448 - 16 Oct 2009
Viewed by 36
Abstract
The Working Group on Cardiovascular Nursing and Allied Professions (WGCNAP) continues to evolve and establish itself as an active working group of the Swiss Society of Cardiology and as the Swiss National Society of Cardiovascular Nursing and Allied Professions [...] Full article
2 pages, 138 KB  
Interesting Images
Diastolic Mitral Regurgitation
by Raban Jeger and Hans Peter Brunner-La Rocca
Cardiovasc. Med. 2009, 12(10), 282; https://doi.org/10.4414/cvm.2009.01447 - 16 Oct 2009
Viewed by 32
Abstract
A 90-year-old female patient was admitted with congestive heart failure [...] Full article
►▼ Show Figures

Figure 1

5 pages, 483 KB  
Editorial
Ist Die Medizin von Sinnen?
by Thomas F. Lüscher
Cardiovasc. Med. 2009, 12(10), 277; https://doi.org/10.4414/cvm.2009.01450 - 16 Oct 2009
Cited by 1 | Viewed by 34
Abstract
Die Aufklärung hat uns Wissen und damit die Technik gebracht, im Alltag und in der Medizin – das sapere aude hat sich durchgesetzt […] Full article
►▼ Show Figures

Figure 1

5 pages, 109 KB  
Editorial
Immunosuppression in Cardiac Transplantation: State of the Art and New Drugs
by Stephan Korom
Cardiovasc. Med. 2009, 12(10), 272; https://doi.org/10.4414/cvm.2009.01454 - 16 Oct 2009
Viewed by 33
Abstract
Although the contemporary armamentarium of immunosuppressive drugs in cardiac transplantation has reduced the incidence and severity of acute rejection, their associated toxicities represent major obstacles to long-term use. A score of new immunosuppressive agents for use in transplantation medicine have entered clinical trials. [...] Read more.
Although the contemporary armamentarium of immunosuppressive drugs in cardiac transplantation has reduced the incidence and severity of acute rejection, their associated toxicities represent major obstacles to long-term use. A score of new immunosuppressive agents for use in transplantation medicine have entered clinical trials. Three small molecules, targeting intracellular pathways (ISA247, a semisynthetic cyclosporine analogue; AEB071, a protein kinase C inhibitor; CP 690550, a Janus kinase 3 inhibitor), and three biologics, immunoglobulins interfering with lymphocyte surface receptor signalling (belatacept, an improved CTLA4Ig; efalizumab, an anti-LFA1-antibody; alefacept, an LFA3-IgG1 fusion receptor protein), are currently being assessed in phase II/III trials. Full article
7 pages, 372 KB  
Editorial
Langzeitergebnisse nach Herztransplantation
by Andreas J. Flammer, Frank Ruschitzka and Matthias Hermann
Cardiovasc. Med. 2009, 12(10), 266; https://doi.org/10.4414/cvm.2009.01453 - 16 Oct 2009
Viewed by 35
Abstract
Long-term survival after heart transplantation has continuously improved for the last centuries. Improvement of donor and recipient selection, better perioperative management and advances in immunosuppression have substationally improved outcome. Survival, however, is still influenced by multiple factors. Beside the prevention of rejection, control [...] Read more.
Long-term survival after heart transplantation has continuously improved for the last centuries. Improvement of donor and recipient selection, better perioperative management and advances in immunosuppression have substationally improved outcome. Survival, however, is still influenced by multiple factors. Beside the prevention of rejection, control of the classical cardiovascular risk factors is crucial. Moreover, the use of immunosuppressive agents should be individualised and complication as tumours and infections should be taken into account. In as much new immunosuppressive.
In as much new immunosuppressive medications will impact on the long-term survival in the future has to be shown. Full article
►▼ Show Figures

Figure 1

4 pages, 167 KB  
Editorial
Links-Ventrikuläre Assist Devices—Indikationen und Möglichkeiten
by Ludwig K. von Segesser, Piergiorgio Tozzi, Enrico Ferrai, Sandra Bommeli, Lars Niclauss, Dominique Delay, Philippe Gersbach, Michel Hurni, Bettina Marty, Patrick Ruchat and Frank Stumpe
Cardiovasc. Med. 2009, 12(10), 260; https://doi.org/10.4414/cvm.2009.01452 - 16 Oct 2009
Viewed by 36
Abstract
Heart failure not responding to medical therapy is either due to left ventricular failure, right ventricular failure or bi-ventricular failure. Left ventricular assist devices are designed for left ventricular mechanical circulatory support and not suitable for treatment of advanced global cardiac failure which [...] Read more.
Heart failure not responding to medical therapy is either due to left ventricular failure, right ventricular failure or bi-ventricular failure. Left ventricular assist devices are designed for left ventricular mechanical circulatory support and not suitable for treatment of advanced global cardiac failure which deteriorates rapidly towards irreversible multi organ failure. Although temporary right ventricular support may be necessary during left mechanical circulatory support, it should be the goal that this is the exception and not the rule. This statement is based on the experience, that predominantly left ventricular failure can be handled well with the timely application of modern implantable left ventricular assist devices which allow usually for relative rapid recovery towards a quite normal life.
We mean here not only weaning from the ventilator, extubation, mobilisation, and the transfer from the intensive care unit to the general hospital ward, but rather the discharge home with a quite good quality of life over a longer time frame despite the machine dependence which requires in our program a weekly outpatient check of the patient with his hard and software. Full article
►▼ Show Figures

Figure 1

2 pages, 109 KB  
Editorial
Herztransplantation Wohin?
by Georg Noll, Frank Ruschitzka and Volkmar Falk
Cardiovasc. Med. 2009, 12(10), 259; https://doi.org/10.4414/cvm.2009.01451 - 16 Oct 2009
Viewed by 30
Abstract
Die Herztransplantation hat die Behandlung von Patienten mit terminaler Herzkrankheit revolutioniert […] Full article
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-7
Previous Issue
Next Issue
Back to TopTop